etidronate has been researched along with Cochlear Hearing Loss in 6 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 2-year prospective double-blind study was performed to evaluate the role of etidronate disodium for the treatment of progressive hearing loss in patients with otosclerosis." | 9.07 | The effects of etidronate disodium on progressive hearing loss from otosclerosis. ( Hoffer, ME; Holliday, M; Kennedy, DW, 1993) |
| "A 2-year prospective double-blind study was performed to evaluate the role of etidronate disodium for the treatment of progressive hearing loss in patients with otosclerosis." | 5.07 | The effects of etidronate disodium on progressive hearing loss from otosclerosis. ( Hoffer, ME; Holliday, M; Kennedy, DW, 1993) |
| "Otosclerosis is a disease of abnormal bone remodeling in the otic capsule." | 1.38 | Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis. ( Halpin, C; McKenna, MJ; Merchant, SN; Quesnel, AM; Seton, M, 2012) |
| "Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production." | 1.35 | Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, S | 1 |
| Walters, B | 1 |
| Eastwood, M | 1 |
| Abou-Foul, AK | 1 |
| Bhimrao, S | 1 |
| Brookler, K | 1 |
| Brookler, KH | 1 |
| Quesnel, AM | 1 |
| Seton, M | 1 |
| Merchant, SN | 1 |
| Halpin, C | 1 |
| McKenna, MJ | 1 |
| Kennedy, DW | 1 |
| Hoffer, ME | 1 |
| Holliday, M | 1 |
| Yaşil, S | 1 |
| Cömlekçi, A | 1 |
| Güneri, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study[NCT04152551] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for etidronate and Cochlear Hearing Loss
| Article | Year |
|---|---|
A Systematic Review of the Effectiveness of Bisphosphonates for Otosclerosis.
Topics: Adult; Child; Diphosphonates; Etidronic Acid; Hearing Loss, Sensorineural; Humans; Otosclerosis; Ret | 2022 |
1 trial available for etidronate and Cochlear Hearing Loss
| Article | Year |
|---|---|
The effects of etidronate disodium on progressive hearing loss from otosclerosis.
Topics: Adult; Aged; Auditory Threshold; Double-Blind Method; Etidronic Acid; Female; Hearing Loss, Bilatera | 1993 |
4 other studies available for etidronate and Cochlear Hearing Loss
| Article | Year |
|---|---|
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined | 2008 |
Monaural diplacusis with tinnitus, aural fullness, hyperacusis, and sensorineural hearing loss.
Topics: Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Etidronic Acid; Hearing Loss, Sensorine | 2009 |
Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.
Topics: Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Bone Conduction; Bone Density Conservation A | 2012 |
Further hearing loss during osteoporosis treatment with etidronate.
Topics: Aged; Etidronic Acid; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Osteoporosis, | 1998 |